

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis c | D006526 | — | B19.2 | — | 2 | — | — | — | 2 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | — | 1 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | 1 | — | — | — | 1 |
| Communicable diseases | D003141 | — | — | — | 1 | — | — | — | 1 |
| Virus diseases | D014777 | — | B34 | — | 1 | — | — | — | 1 |
| Hepatitis | D006505 | — | K75.9 | — | 1 | — | — | — | 1 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 1 | — | — | — | 1 |
| Fatty liver | D005234 | EFO_0003934 | — | — | 1 | — | — | — | 1 |
| Drug common name | NIVOCASAN |
| INN | nivocasan |
| Description | Nivocasan is a small molecule pharmaceutical. It is currently being investigated in clinical studies. |
| Classification | Small molecule |
| Drug class | caspase inhibitors |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)[C@@]1(C(=O)N[C@H]2CC(=O)O[C@]2(O)CF)CC(c2nccc3ccccc23)=NO1 |
| PDB | — |
| CAS-ID | 908253-63-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2105721 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 9554OW6MVU (ChemIDplus, GSRS) |
